Dihydroergotamine nasal spray for the acute treatment of migraine

Dewey K. Ziegler, R. Ford, J. Kriegler, R. M. Gallagher, S. Peroutka, John Hammerstad, J. Saper, M. Hoffert, B. Vogel, N. Holtz, F. Di Serio

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal spray and placebo over 4 hours in the treatment of migraine. Of the 112 patients enrolled, 100 were included in the “intent-to-treat” efficacy analysis. The patients self-administered either 2.0 mg DHE (0.5 mg per nostril, repeated after 15 minutes) or placebo at the onset of two separate headaches and rated hourly the drugs’ effects on pain severity, pain relief, nausea, and vomiting. The physicians assessed the overall effectiveness of the drugs in relieving headache pain, nausea, and vomiting. Both the patients’ and physicians’ ratings indicated that DHE was significantly superior to placebo in improving headache and nausea; according to the patients’ ratings, these between-group differences were already significant at the first (hour 1) evaluation. There were no significant differential treatment effects with respect to relief of vomiting. Most adverse events were mild or moderate, confined to the nasopharyngeal area, and probably related to the route of administration. We conclude that DHE nasal spray is a safe and effective treatment for the pain and nausea of migraine attacks.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalNeurology
Volume44
Issue number3
StatePublished - 1994

Fingerprint

Dihydroergotamine
Nasal Sprays
Migraine Disorders
Nausea
Vomiting
Headache
Pain
Placebos
Physicians
Therapeutics
Pharmaceutical Preparations
Safety
Spray
Nasal
Placebo
Efficacy
Rating
Relief

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Ziegler, D. K., Ford, R., Kriegler, J., Gallagher, R. M., Peroutka, S., Hammerstad, J., ... Di Serio, F. (1994). Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology, 44(3), 447-453.

Dihydroergotamine nasal spray for the acute treatment of migraine. / Ziegler, Dewey K.; Ford, R.; Kriegler, J.; Gallagher, R. M.; Peroutka, S.; Hammerstad, John; Saper, J.; Hoffert, M.; Vogel, B.; Holtz, N.; Di Serio, F.

In: Neurology, Vol. 44, No. 3, 1994, p. 447-453.

Research output: Contribution to journalArticle

Ziegler, DK, Ford, R, Kriegler, J, Gallagher, RM, Peroutka, S, Hammerstad, J, Saper, J, Hoffert, M, Vogel, B, Holtz, N & Di Serio, F 1994, 'Dihydroergotamine nasal spray for the acute treatment of migraine', Neurology, vol. 44, no. 3, pp. 447-453.
Ziegler DK, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44(3):447-453.
Ziegler, Dewey K. ; Ford, R. ; Kriegler, J. ; Gallagher, R. M. ; Peroutka, S. ; Hammerstad, John ; Saper, J. ; Hoffert, M. ; Vogel, B. ; Holtz, N. ; Di Serio, F. / Dihydroergotamine nasal spray for the acute treatment of migraine. In: Neurology. 1994 ; Vol. 44, No. 3. pp. 447-453.
@article{6aaf4fa20d6a4a0ab17b2f7178819f1f,
title = "Dihydroergotamine nasal spray for the acute treatment of migraine",
abstract = "We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal spray and placebo over 4 hours in the treatment of migraine. Of the 112 patients enrolled, 100 were included in the “intent-to-treat” efficacy analysis. The patients self-administered either 2.0 mg DHE (0.5 mg per nostril, repeated after 15 minutes) or placebo at the onset of two separate headaches and rated hourly the drugs’ effects on pain severity, pain relief, nausea, and vomiting. The physicians assessed the overall effectiveness of the drugs in relieving headache pain, nausea, and vomiting. Both the patients’ and physicians’ ratings indicated that DHE was significantly superior to placebo in improving headache and nausea; according to the patients’ ratings, these between-group differences were already significant at the first (hour 1) evaluation. There were no significant differential treatment effects with respect to relief of vomiting. Most adverse events were mild or moderate, confined to the nasopharyngeal area, and probably related to the route of administration. We conclude that DHE nasal spray is a safe and effective treatment for the pain and nausea of migraine attacks.",
author = "Ziegler, {Dewey K.} and R. Ford and J. Kriegler and Gallagher, {R. M.} and S. Peroutka and John Hammerstad and J. Saper and M. Hoffert and B. Vogel and N. Holtz and {Di Serio}, F.",
year = "1994",
language = "English (US)",
volume = "44",
pages = "447--453",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Dihydroergotamine nasal spray for the acute treatment of migraine

AU - Ziegler, Dewey K.

AU - Ford, R.

AU - Kriegler, J.

AU - Gallagher, R. M.

AU - Peroutka, S.

AU - Hammerstad, John

AU - Saper, J.

AU - Hoffert, M.

AU - Vogel, B.

AU - Holtz, N.

AU - Di Serio, F.

PY - 1994

Y1 - 1994

N2 - We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal spray and placebo over 4 hours in the treatment of migraine. Of the 112 patients enrolled, 100 were included in the “intent-to-treat” efficacy analysis. The patients self-administered either 2.0 mg DHE (0.5 mg per nostril, repeated after 15 minutes) or placebo at the onset of two separate headaches and rated hourly the drugs’ effects on pain severity, pain relief, nausea, and vomiting. The physicians assessed the overall effectiveness of the drugs in relieving headache pain, nausea, and vomiting. Both the patients’ and physicians’ ratings indicated that DHE was significantly superior to placebo in improving headache and nausea; according to the patients’ ratings, these between-group differences were already significant at the first (hour 1) evaluation. There were no significant differential treatment effects with respect to relief of vomiting. Most adverse events were mild or moderate, confined to the nasopharyngeal area, and probably related to the route of administration. We conclude that DHE nasal spray is a safe and effective treatment for the pain and nausea of migraine attacks.

AB - We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal spray and placebo over 4 hours in the treatment of migraine. Of the 112 patients enrolled, 100 were included in the “intent-to-treat” efficacy analysis. The patients self-administered either 2.0 mg DHE (0.5 mg per nostril, repeated after 15 minutes) or placebo at the onset of two separate headaches and rated hourly the drugs’ effects on pain severity, pain relief, nausea, and vomiting. The physicians assessed the overall effectiveness of the drugs in relieving headache pain, nausea, and vomiting. Both the patients’ and physicians’ ratings indicated that DHE was significantly superior to placebo in improving headache and nausea; according to the patients’ ratings, these between-group differences were already significant at the first (hour 1) evaluation. There were no significant differential treatment effects with respect to relief of vomiting. Most adverse events were mild or moderate, confined to the nasopharyngeal area, and probably related to the route of administration. We conclude that DHE nasal spray is a safe and effective treatment for the pain and nausea of migraine attacks.

UR - http://www.scopus.com/inward/record.url?scp=0028226660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028226660&partnerID=8YFLogxK

M3 - Article

C2 - 8145914

AN - SCOPUS:0028226660

VL - 44

SP - 447

EP - 453

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -